VAXNEUVANCE elicited robust immune responses against 15 serotypes postdose 3 and 4 in pediatric patients

In the absence of clinical efficacy endpoints, vaccine effectiveness against invasive pneumococcal disease may be inferred by comparing immunogenicity of pneumococcal conjugate vaccines to measure (or evaluate) noninferiority in clinical trials.2

The introduction of PCVs has been effective in reducing IPD in children. However, select serotypes—such as Serotype 3, 22F, and 33F—continue to contribute to the burden of disease.4,19

That’s why immunogenicity against key disease-causing serotypes is important.4,19,20

VAXNEUVANCE delivered a robust immune response against 15 serotypes postdose 3 IgG response rates and postdose 4 GMC ratios, includinga:

Comparable immune responses for 12 shared serotypes found in PCV13

Superior immune responses for shared Serotype 3 vs PCV13b,c

Superior immune responses for unique Serotypes 22F and 33F—not covered by PCV1321

Image Showing Superior Immune Responses to Serotypes 3, 22F, 33F (Secondary Endpoint) and Comparable Immune Response to Serotypes 1,4, 5,6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F (Primary Endpoint). (22)
(Secondary Endpoint)22 (Primary Endpoint)22

Randomized controlled trials assessing the clinical efficacy of VAXNEUVANCE compared to PCV13 have not been conducted.

GMC Ratios, postdose 3a

After a 3-dose primary series, VAXNEUVANCE was found to be noninferior to PCV13 for
12 out of 13 shared serotypes based on the lower bound of the 2-sided 95% CI for the GMC ratio (VAXNEUVANCE/PCV13) being >0.5. For VAXNEUVANCE, the lgG GMC for serotype 6A was just below the noninferiority criteria by a small margin, with the lower bound of the 2-sided 95% CI for the GMC ratio being 0.48 compared to the required criteria of >0.5 for noninferiority.

aMeasurements were taken 30 days postdose specified.
bPostdose 3 IgG response rate percentage point difference vs PCV13, 19.1 (95% CI: 14.4, 24.0).
cPostdose 4 IgG GMC ratio vs PCV13, 1.43 (95% CI: 1.30, 1.57).

Study Design

Study 8 was a pivotal, double-blind, active comparator-controlled study in which participants were randomized to receive VAXNEUVANCE (N=860) or PCV13 (N=860) in a 4-dose series. The first 3 doses were administered to infants at 2, 4, and 6 months of age and the fourth dose was administered to children at 12 through 15 months of age. Participants also received other licensed pediatric vaccines concomitantly. Immune responses were measured by IgG response rates, IgG GMCs, and OPA GMTs for all 15 serotypes contained in VAXNEUVANCE.

CI, confidence interval; GMC, geometric mean concentration (mcg/mL); GMT, geometric mean titer;
IgG, Immunoglobulin G; IPD, invasive pneumococcal disease; OPA, opsonophagocytic activity;
PCV, pneumococcal conjugate vaccine; PCV13, 13-valent pneumococcal conjugate vaccine.

Assess immune response vs PCV13

Immune Response

Learn about specific populations

Specific Populations

Stay updated on the burden of IPD

Burden of IPD

View safety & tolerability data

Safety & Tolerability

pediatric-ref2

Reference

  1. Recommendations to assure the quality, safety and efficacy of pneumococcal conjugate vaccines, Annex 3, TRS No 977. World Health Organization. October 19, 2013. Accessed January 26, 2024. https://www.who.int/publications/m/item/pneumococcal-conjugate-vaccines-annex3-trs-977
pediatric-ref4

Reference

  1. Gierke R, Wodi P, Kobayashi M. Epidemiology and Prevention of Vaccine-Preventable Diseases (Pink Book). 14th edition. Chapter 17: Pneumococcal disease. Centers for Disease Control and Prevention. Last reviewed August 18, 2021. Accessed April 19, 2023. https://www.cdc.gov/vaccines/pubs/pinkbook/pneumo.html
pediatric-ref10

Reference

  1. Immunizations. American Academy of Pediatrics (AAP). Last updated July 10, 2023. Accessed January 2, 2024. https://www.aap.org/en/patient-care/immunizations/
pediatric-ref11

Reference

  1. American Academy of Family Physicians (AAFP). Immunization schedules. 2024. Accessed November 29, 2023. https://www.aafp.org/family-physician/patient-care/prevention-wellness/immunizations-vaccines/immunization-schedules.html
pediatric-ref19

Reference

  1. Centers for Disease Control and Prevention (CDC). Visualization – Based on 2016-2021 serotype data for invasive pneumococcal disease cases by age group from Active Bacterial Core surveillance (ABCs). Updated September 29, 2023. Accessed October 19, 2023. https://data.cdc.gov/d/qvzb-qs6p/visualization
pediatric-ref20

Reference

  1. Hu T, Weiss T, Owusu-Edusei K, Petigara T. Health and economic burden associated with 15-valent pneumococcal conjugate vaccine serotypes in children in the United States. J Med Econ. 2020;23(12):1653-1660. doi:10.1080/13696998.2020.1840216
pediatric-ref21

Reference

  1. Prevnar 13. Prescribing Information. Pfizer, Inc.; 2019.
pediatric-ref22

Reference

  1. Lupinacci R, Rupp R, Wittawatmongkol O, et al. A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants (PNEU-PED). Vaccine. 2023;41(5):1142-1152. doi:10.1016/j.vaccine.2022.12.054
pediatric-ref28

Reference

  1. Pittet LF, Posfay-Barbe KM. Vaccination of immune compromised children—an overview for physicians. Eur J Pediatr. 2021;180(7):2035-2047. doi:10.1007/s00431-021-03997-1
patient

You are about to leave MerckVaccines.com

Patient Website – https://www.vaxneuvance.com/pediatrics

CANCEL
CONTINUE

Thank you for visiting.

Indications and Usage for VAXNEUVANCE

VAXNEUVANCE is indicated for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F in individuals 6 weeks of age and older.

Select Safety Information for VAXNEUVANCE

Do not administer VAXNEUVANCE to individuals with a severe allergic reaction (eg, anaphylaxis) to any component of VAXNEUVANCE or to diphtheria toxoid.

Some individuals with altered immunocompetence, including those receiving immunosuppressive therapy, may have a reduced immune response to VAXNEUVANCE.

Apnea following intramuscular vaccination has been observed in some infants born prematurely. Vaccination of premature infants should be based on the infant’s medical status and the potential benefits and possible risks.

The most commonly reported solicited adverse reactions in children vaccinated at 2, 4, 6, and 12 through 15 months of age, provided as a range across the 4-dose series, were: irritability (57.3% to 63.4%), somnolence (24.2% to 47.5%), injection-site pain (25.9% to 40.3%), fever ≥38.0°C (13.3% to 20.4%), decreased appetite (14.1% to 19.0%), injection-site induration (13.2% to 15.4%), injection-site erythema (13.7% to 21.4%), and injection-site swelling (11.3% to 13.4%).

The most commonly reported solicited adverse reactions in children 2 through 17 years of age vaccinated with a single dose were: injection-site pain (54.8%), myalgia (23.7%), injection-site swelling (20.9%), injection-site erythema (19.2%), fatigue (15.8%), headache (11.9%), and injection-site induration (6.8%).

The reported solicited adverse reactions in children 7 through 11 months of age who received 3 doses of VAXNEUVANCE were: fever ≥38.0°C (21.9%), irritability (32.8%), injection-site erythema (28.1%), somnolence (21.9%), injection-site swelling (18.8%), injection-site pain (18.8%), injection-site induration (17.2%), decreased appetite (15.6%), and urticaria (1.6%).

The reported solicited adverse reactions in children 12 through 23 months of age who received 2 doses of VAXNEUVANCE were: fever ≥38.0°C (11.3%), irritability (35.5%), injection-site pain (33.9%), somnolence (24.2%), decreased appetite (22.6%), injection-site erythema (21.0%), injection-site swelling (14.5%), and injection-site induration (8.1%).

Vaccination with VAXNEUVANCE may not protect all vaccine recipients.

Before administering VAXNEUVANCE, please read the accompanying Prescribing Information. The Patient Information also is available.

Indications and Usage for VAXNEUVANCE® (Pneumococcal 15-valent Conjugate Vaccine)

VAXNEUVANCE is indicated for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F in individuals 6 weeks of age and older.

VAXNEUVANCE is indicated for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae

VAXNEUVANCE is indicated for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F in individuals 6 weeks of age and older.

Select Safety Information for VAXNEUVANCE® (Pneumococcal 15-valent Conjugate Vaccine)

Do not administer VAXNEUVANCE to individuals with a severe allergic reaction (eg, anaphylaxis) to any component of VAXNEUVANCE or to diphtheria toxoid.

Some individuals with altered immunocompetence, including those receiving immunosuppressive therapy, may have a reduced immune response to VAXNEUVANCE.

Apnea following intramuscular vaccination has been observed in some infants born prematurely. Vaccination of premature infants should be based on the infant’s medical status and the potential benefits and possible risks.

The most commonly reported solicited adverse reactions in children vaccinated at 2, 4, 6, and 12 through 15 months of age, provided as a range across the 4-dose series, were: irritability (57.3% to 63.4%), somnolence (24.2% to 47.5%), injection-site pain (25.9% to 40.3%), fever ≥38.0°C (13.3% to 20.4%), decreased appetite (14.1% to 19.0%), injection-site induration (13.2% to 15.4%), injection-site erythema (13.7% to 21.4%), and injection-site swelling (11.3% to 13.4%).

The most commonly reported solicited adverse reactions in children 2 through 17 years of age vaccinated with a single dose were: injection-site pain (54.8%), myalgia (23.7%), injection-site swelling (20.9%), injection-site erythema (19.2%), fatigue (15.8%), headache (11.9%), and injection-site induration (6.8%).

The reported solicited adverse reactions in children 7 through 11 months of age who received 3 doses of VAXNEUVANCE were: fever ≥38.0°C (21.9%), irritability (32.8%), injection-site erythema (28.1%), somnolence (21.9%), injection-site swelling (18.8%), injection-site pain (18.8%), injection-site induration (17.2%), decreased appetite (15.6%), and urticaria (1.6%).

The reported solicited adverse reactions in children 12 through 23 months of age who received 2 doses of VAXNEUVANCE were: fever ≥38.0°C (11.3%), irritability (35.5%), injection-site pain (33.9%), somnolence (24.2%), decreased appetite (22.6%), injection-site erythema (21.0%), injection-site swelling (14.5%), and injection-site induration (8.1%).

Vaccination with VAXNEUVANCE may not protect all vaccine recipients.

Before administering VAXNEUVANCE, please read the accompanying Prescribing Information. The Patient Information also is available.

Do not administer VAXNEUVANCE to individuals with a severe allergic reaction (eg, anaphylaxis) to any component of VAXNEUVANCE or

Do not administer VAXNEUVANCE to individuals with a severe allergic reaction (eg, anaphylaxis) to any component of VAXNEUVANCE or to diphtheria toxoid.

Some individuals with altered immunocompetence, including those receiving immunosuppressive therapy, may have a reduced immune response to VAXNEUVANCE.

vaxRef

You are about to leave MerckVaccines.com

VAXELIS® (Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus b Conjugate and Hepatitis B Vaccine)

https://www.vaxelis.com

CANCEL
CONTINUE

Thank you for visiting.

US-PVC-01520 02/24